EPOGEN/PROCRIT Drug Profile

Summary for Tradename: EPOGEN/PROCRIT

High Confidence Patents:	5
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for EPOGEN/PROCRIT

Recent Clinical Trials for EPOGEN/PROCRIT

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Sandoz	Phase 3

See all EPOGEN/PROCRIT clinical trials

Pharmacology for EPOGEN/PROCRIT

Physiological Effect	Increased Erythroid Cell Production
Established Pharmacologic Class	Erythropoiesis-stimulating Agent
Chemical Structure	Erythropoietin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for EPOGEN/PROCRIT Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for EPOGEN/PROCRIT Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234		2007-10-23	DrugPatentWatch analysis and company disclosures
Amgen Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234		2015-06-07	DrugPatentWatch analysis and company disclosures
Amgen Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234		2015-06-06	DrugPatentWatch analysis and company disclosures
Amgen Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234		2015-06-06	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for EPOGEN/PROCRIT Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234		2036-12-20	Patent claims search
Amgen Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234		2034-03-14	Patent claims search
Amgen Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234		2037-03-31	Patent claims search
Amgen Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234		2036-11-15	Patent claims search

International Patents for EPOGEN/PROCRIT

Country	Patent Number	Estimated Expiration
New Zealand	227326
Japan	H0435159
Czech Republic	443885
Denmark	365185

Supplementary Protection Certificates for EPOGEN/PROCRIT

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
10199059	Germany		PRODUCT NAME: DARBEPOETIN ALFA; REGISTRATION NO/DATE: EU/1/01/185/001-030 20010608
SPC/GB01/055	United Kingdom		PRODUCT NAME: DARBEPOETIN ALFA; REGISTERED: UK EU/1/01/185/001-030 20010608
01C0050	France		PRODUCT NAME: DARBEPOETIN ALFA; REGISTRATION NO/DATE: EU/1/01/185/001 20010608
300075	Netherlands		PRODUCT NAME: DARBEPOETIN ALFA; REGISTRATION NO/DATE: EU/1/01/185/001 20010608

Market Dynamics and Financial Trajectory for EPOGEN/PROCRIT

Last updated: January 5, 2026

Executive Summary

EPOGEN (epoetin alfa) and PROCRIT are recombinant human erythropoietins developed by Amgen, serving to treat anemia primarily in chronic kidney disease (CKD) and oncology settings. Over the past decade, the market landscape has evolved due to biosimilar entries, regulatory shifts, and changing clinical practices. This analysis explores the current and projected market dynamics, financial trajectories, competitive landscape, and key factors influencing growth prospects.

---

What Are EPOGEN and PROCRIT?

Product Name	Active Ingredient	Indications	Approval Year	Manufacturer
EPOGEN	Epoetin alfa	Anemia in CKD, oncology	1989	Amgen
PROCRIT	Epoetin alfa	Same as EPOGEN	1991	Amgen

Note: Both products are biosimilars, with PROCRIT being a biosimilar version introduced post-patent expiry.

---

Market Overview and Historical Trends

Global Market Size & Growth (2018-2022)

Year	Estimated Global Revenue (USD Billion)	CAGR (%)	Key Drivers
2018	2.1	—	CKD prevalence, oncology use
2019	2.3	9.5	Increased adoption
2020	2.4	4.3	Pandemic impact, stockpiling
2021	2.6	8.3	Recovery & biosimilar expansion
2022	2.75	5.8	Market stabilization, biosimilar penetration

Source: Grand View Research, 2022[1].

Indications Driving Revenue

• Chronic Kidney Disease (CKD): Main application; anemia management in dialysis and nondialysis patients.
• Oncology Support: Anemia secondary to chemotherapy.
• Surgical & Other Uses: Erythropoiesis stimulation to reduce transfusions.

---

Market Drivers

Factor	Impact	Notes
Increasing CKD Incidence	Growing demand	~10% annual increase in CKD globally [2]
Biosimilar Competition	Price erosion	Entry of biosimilars starting 2017 in EU and US
Regulatory Changes	Practice shifts	FDA and EMA safety warnings (2010s) reduced use in some settings
New Administration Guidelines	Usage restrictions	Limits on use in cancer-related anemia

---

Competitive Landscape: Original vs. Biosimilars

Product Type	Number of Market Players (2023)	Price Impact	Market Share (Estimated)
Originators (EPOGEN/PROCRIT)	2 (Amgen, Johnson & Johnson)	Stable but declining	~60% of total revenue
Biosimilars	6+ globally	Significant price reductions (~20-40%)	~40% of total revenue

Note: Major biosimilar entrants include Sandoz, Bio-Thera, and other regional players.

---

Financial Trajectory & Forecast

Revenue Projections (2023-2027)

Year	Estimated Global Revenue (USD Billion)	Growth Rate (YOY)	Key Assumptions
2023	2.8	+2%	Stabilization of biosimilar adoption
2024	2.75	-1.8%	Slight decline due to market saturation
2025	2.9	+5.5%	New indications, emerging markets
2026	3.1	+6.9%	Expanded biosimilar market penetration
2027	3.3	+6.5%	Growing CKD prevalence, biosimilar competition

Note: The forecast incorporates biosimilar price erosion, regulatory impacts, and expanding indications.

Pricing Trends

Year	Average Selling Price (USD per unit)	Trend	Key Factors
2018	10	Stable	Originator dominance
2022	7	Decline	Biosimilar competition, market pressures
2024	6.8	Continued decline	Volume growth compensates margin loss

---

Key Market Influencers

Regulatory Environment

• FDA & EMA Warnings (2010s): Cautioned against high-dose ESA use due to increased cardiovascular risks.
• Biosimilar Approval Pathways: EMA approved the first biosimilar epoetin in 2007; FDA began approving biosimilar epoetins starting in 2018.
• Reimbursement Policies: Shifts towards value-based care in US and Europe influence prescribing behaviors.

Clinical Practice Changes

• Reduced ESA dosing and usage frequency.
• Preference for alternative anemia management strategies.
• Emphasis on individualized therapy.

Emerging Market Expansion

• Increasing adoption in Asia-Pacific, Latin America, driven by rising CKD prevalence.
• Lower healthcare costs and biosimilar accessibility boost market penetration.

---

Comparative Analysis: EPOGEN/PROCRIT vs. Other Hematopoietic Agents

Parameter	Erythropoietins (EPOGEN/PROCRIT)	Hematopoietic Growth Factors (e.g., G-CSF)	Advantages	Limitations
Indications	Anemia in CKD, cancer	Neutropenia, bone marrow stimulation	Established safety profile	Price erosion, biosimilar competition
Market Size	~$2.75B (2022)	~$1B (G-CSF agent market)	Wide use	Safety concerns with high doses
Biosimilar Impact	Significant	Moderate	Lower costs for providers	Market saturation

---

Future Outlook: Opportunities and Challenges

Opportunities	Challenges
Expansion into emerging markets	Stringent safety regulations
Innovative formulations (e.g., longer-acting versions)	Competition from newer agents (e.g., HIF stabilizers)
Broadened indications (e.g., anemia in non-CKD chronic diseases)	Reimbursement and policy restrictions
Digital/Analytical tools for tailored therapy	Patent expirations leading to biosimilar proliferation

---

Deep Dive: Competitive Strategies for Stakeholders

Stakeholder	Strategic Focus	Recommended Actions
Original Manufacturers	Maintain market share	Invest in biosimilars, differentiate via patient management programs
Biosimilar Producers	Capture price-sensitive segments	Focus on regional markets, optimize supply chains
Healthcare Providers	Optimize cost-effectiveness	Implement guidelines informed by safety data
Regulators	Ensure safety and access	Facilitate biosimilar approval, monitor adverse events

---

Conclusion

The EPOGEN/PROCRIT market is characterized by maturation, biosimilar proliferation, and evolving clinical practice standards. While overall revenue remains significant, growth is tempered by biosimilar competition and safety considerations. Strategic differentiation, expanding into emerging markets, and innovation in administration are vital for sustaining long-term financial trajectories. Continuous monitoring of regulatory updates and clinical guidelines will shape future market dynamics, influencing revenue streams and stakeholder strategies.

---

Key Takeaways

• The global EPOGEN/PROCRIT market was approximately USD 2.75 billion in 2022, with modest growth expected through 2027.
• Biosimilars now comprise around 40% of the market, exerting downward pressure on prices.
• Growth opportunities lie in emerging markets, new indications, and longer-acting formulations, despite regulatory and safety challenges.
• Safety concerns and clinical practice shifts have restrained some use, necessitating strategic repositioning.
• Success depends on balancing cost, safety, and innovative offerings amid a competitive landscape marked by patent expirations and biosimilar proliferation.

---

FAQs

1. How have biosimilars impacted the market for EPOGEN/PROCRIT?

Biosimilars introduced since 2017 have led to price reductions of up to 40%, increasing market competition and eroding profit margins for originator products. They now account for approximately 40% of the global market share, incentivizing providers to switch to cost-effective options.

2. What is the outlook for EPOGEN/PROCRIT in emerging markets?

Emerging markets show strong growth potential due to increasing CKD prevalence, rising healthcare infrastructure, and biosimilar acceptance. Market entry strategies targeting affordability and regulatory compliance could position firms favorably.

3. How are regulatory changes affecting EPOGEN/PROCRIT use?

Regulatory agencies, notably the FDA and EMA, issued safety warnings over ESA-related cardiovascular risks, leading to more stringent indications and dosing protocols. This has resulted in reduced use in certain populations, impacting revenue streams.

4. Are there alternative therapies affecting the EPOGEN/PROCRIT market?

Yes, hypoxia-inducible factor (HIF) stabilizers, such as roxadustat, are emerging as oral alternatives with different safety profiles, potentially shifting the landscape of anemia management.

5. What future innovations could influence the EPOGEN/PROCRIT market?

Long-acting formulations, personalized dosing algorithms, and integration with digital health tools are anticipated to enhance efficacy, safety, and patient adherence, creating new revenue opportunities.

---

References

[1] Grand View Research. (2022). "Erythropoietin Market Size, Share & Trends Analysis Report."
[2] United Nations. (2019). "Global Prevalence of Chronic Kidney Disease."
[3] FDA. (2019). "Safety Communication: Recommendations for Erythropoiesis-Stimulating Agents."
[4] EMA. (2021). "Guidelines on Biosimilar Medicines."